The need for a subsequent transvenous system in patients implanted with subcutaneous implantable cardioverter defibrillator.
暂无分享,去创建一个
A. Curnis | M. Biffi | M. Bertini | M. Ziacchi | A. Dello Russo | C. Lavalle | R. Tilz | L. Calò | C. Tondo | M. Laredo | S. Gulletta | C. Pignalberi | P. Compagnucci | M. Casella | J. Kuschyk | A. Breitenstein | E. Pisano | G. Forleo | L. Santini | D. Ricciardi | A. Gasperetti | G. Mitacchione | P. Palmisano | J. Vogler | S. De Bonis | F. Vitali | R. Arosio | L. Kaiser | F. Picarelli | N. Badenco | M. Schiavone | F. Fastenrath | A. Angeletti | E. Pisanò | Silvana De Bonis
[1] OUP accepted manuscript , 2022, European Heart Journal.
[2] P. Lambiase,et al. Efficacy and Safety of Appropriate Shocks and Antitachycardia Pacing in Transvenous and Subcutaneous Implantable Defibrillators: Analysis of All Appropriate Therapy in the PRAETORIAN Trial , 2021, Circulation.
[3] M. Glikson,et al. The '10 commandments' for the 2021 ESC guidelines on cardiac pacing and cardiac resynchronization therapy. , 2021, European heart journal.
[4] A. Natale,et al. Intraprocedural PRAETORIAN score for early assessment of S‐ICD implantation: A proof‐of‐concept study , 2021, Journal of cardiovascular electrophysiology.
[5] A. Curnis,et al. Long term complications in patients implanted with subcutaneous implantable defibrillators Real-world data from the Extended ELISIR experience. , 2021, Heart rhythm.
[6] L. Di Biase,et al. Subcutaneous implantable cardioverter defibrillator and defibrillation testing: a propensity-matched pilot study. , 2021, Heart rhythm.
[7] P. Lambiase,et al. Device-related Infection in De Novo Transvenous Implantable Cardioverter-Defibrillator Medicare Patients. , 2021, Heart rhythm.
[8] M. Biffi,et al. Clinical impact of defibrillation testing in a real‐world S‐ICD population: Data from the ELISIR registry , 2020, Journal of cardiovascular electrophysiology.
[9] M. Casula,et al. Subcutaneous versus Transvenous Implantable Defibrillator: an updated Meta-analysis. , 2020, Heart rhythm.
[10] A. Curnis,et al. Neglected lead tip erosion: An unusual case of S‐ICD inappropriate shock , 2020, Journal of cardiovascular electrophysiology.
[11] P. Lambiase,et al. Subcutaneous or Transvenous Defibrillator Therapy , 2020, New England Journal of Medicine.
[12] George A. Johnson,et al. Long-Term Outcomes of Implantable Cardioverter-Defibrillator Therapy in the SCD-HeFT. , 2020, Journal of the American College of Cardiology.
[13] R. Khouzam,et al. Implantable Cardioverter Defibrillators and Chronic Kidney Disease. , 2020, Current problems in cardiology.
[14] W. Zareba,et al. Need for pacing in patients who qualify for an implantable cardioverter‐defibrillator: Clinical implications for the subcutaneous ICD , 2020, Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc.
[15] M. Biffi,et al. Successful defibrillation verification in subcutaneous implantable cardioverter‐defibrillator recipients by low‐energy shocks , 2019, Clinical cardiology.
[16] A. Wilde,et al. A novel tool to evaluate the implant position and predict defibrillation success of the subcutaneous implantable cardioverter-defibrillator: The PRAETORIAN score. , 2019, Heart rhythm.
[17] F. Prinzen,et al. Atrioventricular dromotropathy: evidence for a distinctive entity in heart failure with prolonged PR interval? , 2018, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[18] J. DiNicolantonio,et al. Subcutaneous Versus Transvenous Implantable Defibrillator Therapy: A Meta-Analysis of Case-Control Studies. , 2017, JACC. Clinical electrophysiology.
[19] A. Wilde,et al. Long-Term Clinical Outcomes of Subcutaneous Versus Transvenous Implantable Defibrillator Therapy. , 2016, Journal of the American College of Cardiology.
[20] M. Falagas,et al. Risk factors for cardiac implantable electronic device infection: a systematic review and meta-analysis. , 2015, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[21] A. Auricchio,et al. Low inappropriate shock rates in patients with single- and dual/triple-chamber implantable cardioverter-defibrillators using a novel suite of detection algorithms: PainFree SST trial primary results. , 2015, Heart rhythm.
[22] Pier D. Lambiase,et al. Safety and Efficacy of the Totally Subcutaneous Implantable Defibrillator: 2-Year Results From a Pooled Analysis of the IDE Study and EFFORTLESS Registry. , 2015, Journal of the American College of Cardiology.
[23] D. Babuty,et al. Reduced risk for inappropriate implantable cardioverter-defibrillator shocks with dual-chamber therapy compared with single-chamber therapy: results of the randomized OPTION study. , 2014, JACC. Heart failure.
[24] P. Lambiase,et al. Worldwide experience with a totally subcutaneous implantable defibrillator: early results from the EFFORTLESS S-ICD Registry , 2014, European heart journal.
[25] C. Swerdlow,et al. Antitachycardia Pacing in Primary‐Prevention ICDs , 2010, Journal of cardiovascular electrophysiology.
[26] J. Jiménez-Candil,et al. Influence of beta-blocker therapy on antitachycardia pacing effectiveness for monomorphic ventricular tachycardias occurring in implantable cardioverter-defibrillator patients: a dose-dependent effect. , 2010, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[27] Alexander H Maass,et al. An entirely subcutaneous implantable cardioverter-defibrillator. , 2010, The New England journal of medicine.
[28] A. Camm,et al. Single-chamber versus dual-chamber pacing for high-grade atrioventricular block. , 2005, The New England journal of medicine.